CD4 and melanoma: Another study of 4 patients with advanced melanoma found that ipilimumab generated or augmented multiple T helper type 1 (Th1) dominant CD4+ T cell responses, seen by analysis of in vitro cultured CD4+ T cells isolated from patients’ peripheral blood (11).